Over-Optimistic Portrayal of Life-Supporting Treatments in Newspapers and Internet
By Thaddeus Pope,
Medical Futility Blog
| 08. 09. 2014
Several Taiwanese researchers have
just published a new study: "Over-Optimistic Portrayal of Life-Supporting Treatments in Newspapers and on the Internet: A Cross-Sectional Study Using Extra-Corporeal Membrane Oxygenation as an Example."
From the article's conclusion: Newspapers and the Internet have the potential to influence patients' knowledge and attitudes toward medical decision-making by providing over-optimistic medical information through the following ways:
- First, the mass media tend to attract the public’s attention by reporting the positive outcome of an important breakthrough in clinical medicine
- Second, the mass media tend to report patients who survive to hospital discharge, rather than those who die during hospital stay
- Third, the survived patients and their stories are more likely to be duplicated in newspapers and on Internet web pages than those who die during hospital stay.
Newspaper readers and Internet users may, therefore, mistakenly believe that ECMO can usually rescue patients from all life-threatening conditions. However, ECMO, similar to other aggressive LST such as CPR, is ethically appropriate to be initiated on patients with
reversible diseases, not on those with irreversible diseases.
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Eric Schmidt, TIME | 04.16.2024
Imagine a world where everything from plastics to concrete is produced from biomass. Personalized cell and gene therapies prevent pandemics and treat previously incurable genetic diseases. Meat is lab-grown; enhanced nutrient grains are climate-resistant. This is what the future could...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Jorge Barrera and Rachel Houlihan, CBC | 04.09.2024
A Canadian DNA laboratory knowingly delivered prenatal paternity test results that routinely identified the wrong biological fathers — ruling out the real dads — and left a trail of shattered lives around the globe, a CBC News investigation has found...